Scaling a peptide program involves more than installing a larger reactor. The buyer needs the same defined material at a larger output, with agreed analytical methods and reproducible records. Changes in coupling, purification and handling can change the impurity profile or yield. The practical qualification question is whether the supplier can show control at the requested scale.
Commercial capacity is expanding
PolyPeptide began production with new large-scale solid-phase peptide synthesis (SPPS) capacity at Braine-l’Alleud in December 2024. CordenPharma says its Colorado expansion is planned to bring total SPPS reactor capacity above 42,000 L by 2028, while a Swiss facility will add more than 5,000 L. These are useful indicators of industry investment, but reactor litres are not a substitute for a qualified process for a particular molecule.
Where scale changes the evidence requirement
At larger scale, a team should compare the pilot and proposed commercial routes: resin and building-block controls, coupling and deprotection, cleavage, purification, drying, packaging and storage. The EMA synthetic-peptide guideline emphasizes characterization and impurity control, including complementary analytical methods where co-elution is a risk. Those principles are useful for structuring a buyer’s technical questions even when a specific project is outside the guideline’s regulatory scope.
Flow synthesis and alternative routes may improve a particular process, but a technology claim should be supported by product-specific performance data. A 2025 review describes both progress and unresolved challenges in continuous-flow peptide synthesis. It does not mean every sequence can be transferred to flow at commercial scale.
A scale-up comparison table for the RFQ
- Identity: sequence, salt/counterion, molecular form and reference standard.
- Quality: agreed purity, content, key impurities and method suitability.
- Reproducibility: batch history at relevant scale, yield ranges and deviation handling.
- Supply: sample quantity, proposed lot size, packaging, lead time and change-control process.
- Documents: sample and offered-lot COAs, chromatograms and any additional agreed tests.
Ask the supplier to show how a qualification sample connects to the material actually offered for purchase. That link is more useful than a plant-level capacity number alone.
Sources
PolyPeptide production announcement; CordenPharma capacity announcement; EMA synthetic-peptide guideline; Continuous-flow synthesis review.
Professional sourcing overview. Confirm technical capabilities, regulatory scope and batch results for the specific proposed material.